Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

Inclusion Criteria: 1. Age ≥ 18 years old; 2. Subjects with a diagnosis of B-cell acute lymphoblastic leukemia according to the 2016 edition of the WHO classification criteria for acute leukemia; 3. Subjects whose chromosomal and fusion gene analysis showed positivity for the Ph chromosome, BCR/ABL1 fusion gene; 4. Leukemia cells were CD19 and CD22 positive; 5. Patients with newly diagnosed B-ALL were not treated with standard chemotherapy regimens; 6. Serum total bilirubin ≤ 51 mol/L, serum ALT and AST both ≤ 3 times the upper limit of the normal range, blood creatinine ≤ 176.8 mol/L; 7. Echocardiography showed a left ventricular ejection fraction (LVEF) ≥50%; 8. Subjects had no active pulmonary infection and oxygen saturation ≥92% without oxygen; 9. The prognosis for survival is more than 3 months; 10. ECOG score 0-2; 11. Subjects volunteered to participate in this trial and signed an informed consent form. Exclusion Criteria: Subjects with any of the following exclusion criteria were not eligible for enrollment in this trial: 1. Those with a history of epilepsy or other central nervous system disorders; 2. Those with a history of prolonged QT period or severe cardiac disease; 3. Women who are pregnant or breastfeeding (the safety of this therapy for the unborn child is not known); 4. Those with uncontrolled active infection; 5. Active hepatitis B or hepatitis C virus infection; 6. Those who have previously used any gene therapy product; 7. Those with insufficient amplification (\<5-fold) in response to CD3/CD28 co-stimulatory signals; 8. Creatinine \> 2.5 mg/dl or ALT / AST \> 3 times the upper limit of the normal range or bilirubin \> 2.0 mg/dl; 9. Those who suffer from other uncontrolled medical conditions that, in the opinion of the investigator, make them unsuitable for enrollment; 10. HIV-infected persons; 11. Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the results of the test.